Metalloproteases play a complex role in tumor progression. While the activity of some ADAM, ADAMTS and matrix metalloproteases (MMPs) seems to be protumorigenic, the activity of others seems to prevent tumor progression. The identification of the array of substrates of a given metalloprotease (degradome) seems an adequate approach to predict the effect of the inhibition of a metalloprotease in tumors. Here, we present the proteomic identification of a novel substrate for ADAM10 and -17. We used SILAC (Stable Isotope Labeling by Amino acids in Cell culture), a proteomic technique based on the differential metabolic labeling of cells in different conditions. This was applied to MCF7 cells derived from an invasive mammary tumor, and the same cells expressing shRNAs that knock down ADAM10 or -17. Following this approach, we have identified C4.4A as a substrate to both metalloproteases. Since C4.4A is likely involved in tumor invasion, these results indicate that the cleavage of C4.4A by ADAM10 and ADAM17 contributes to tumor progression.
Introduction
The participation of extracellular matrix degrading metalloproteases in tumor invasion and metastasis has been well documented (Kim et al., 1998; Ohtani, 1998; Kang et al., 2003; Arribas et al., 2006; Golubkov and Strongin, 2007; Mochizuki and Okada, 2007) . Initially, it was proposed that the main, and perhaps only, role of the numerous members of the different metalloprotease families was to clear the path for migrating cells by degrading components of the extracellular matrix. This view changed during the last decade with the realization that some metalloproteases are components of sophisticated signaling pathways that control cell adhesion, migration and proliferation. For example, certain matrix metalloproteases (MMPs) are thought to proteolytically activate receptors that promote tumor invasion (recently reviewed in Nagase et al., 2006) . Furthermore, metalloproteases of the ADAM (A Disintegrin and Metalloprotease domain) and ADAMTS (ADAMs containing thrombospondin domains) families have been shown to modulate cell migration as well as cell proliferation by cleaving cell adhesion molecules, growth factors and growth factor receptors (reviewed in Arribas et al., 2006) . Thus, in addition to degrading extracellular matrix components, some metalloproteases of the MMP, ADAM and ADAMTS families play very specific roles in signaling pathways that promote cell proliferation and migration.
While some metalloproteases clearly contribute to tumor progression, accumulating evidence shows that at least one ADAM (ADAM23) and several ADAMTS and MMPs have anti-tumoral activities, such as inhibition of angiogenesis, activation of antiproliferative growth factors or inhibition of metastasis (Lopez-Otin and Matrisian, 2007) . These unanticipated functions likely explain, at least in part, the lack of success of clinical trials with nonspecific metalloprotease inhibitors (Coussens et al., 2002; Overall and Lopez-Otin, 2002) . However, this failure should not obscure the fact that specific inhibitors for certain protumorigenic metalloproteases could be used in anti-tumor therapy. For example, inhibitors of ADAM10 and ADAM17 (also known as tumor necrosis factor-a converting enzyme, TACE) could interfere with the progression of certain tumors because of the involvement of these metalloproteases in the activation of the epidermal growth factor receptor (EGFR) signaling pathway.
The EGFR and related receptors are overactivated in several tumors of epithelial and mesenchymal origin (Yarden and Sliwkowski, 2001) . The ligands of the EGFRs form a large family of type I transmembrane proteins (Harris et al., 2003) that are cleaved by ADAM10 and ADAM17 (Peschon et al., 1998; Montero et al., 2000; Merlos-Suarez et al., 2001; Sunnarborg et al., 2002; Sahin et al., 2004; Horiuchi et al., 2005; Sahin and Blobel, 2007) . Some of the ligands, such as pro-transforming growth factor-a (proTGF-a) are inactive when membrane anchored. In these cases the proteolytic cleavage can be considered an activation step . In fact, inhibitors of ADAM10 and -17 have been proposed in combination with drugs targeting the EGFRs (Zhou et al., 2006 ) to achieve a more robust inhibition of the EGFR pathway in clinical settings.
The term degradome has been proposed to describe the array of substrates of a given protease (Lopez-Otin Upper panel: ADAM10 shRNA results in the knock-down of its target protein when activated by doxycycline and scrambled shRNA has no effect on ADAM10 expression. Both results illustrate that the used ADAM10 shRNA knocks down ADAM10 levels significantly and that this is not due to unspecific effects of overexpressing shRNA in general. Lower panel: likewise, a stable cell line for ADAM17 shows a clear reduction in both proform and active forms of ADAM17 protein, with the scrambled shRNA having no effect. . The identification of its degradome seems an adequate approach to predict the effect of the inhibition of a metalloprotease in tumor development. ADAM10 and -17 seem to have a particularly large degradome (reviewed in Arribas and Merlos-Suarez, 2003) and they cleave many molecules not related to the EGFR that should be taken into account before further considering these metalloproteases as therapeutic targets. Furthermore, few studies have been carried out with cell lines derived from human tumors, where the identification of additional substrates is likely more informative on the therapeutic potential of the inhibition of ADAM10 and -17.
Here, we present the search for novel ADAM10 and -17 substrates by SILAC (Stable Isotope Labeling by Amino acids in Cell culture), a proteomic technique based on the differential metabolic labeling of cells in different conditions. We have applied this to MCF cells, derived from an invasive mammary tumor, and the same cells expressing shRNAs that knock down ADAM10 or -17. Following this approach, we have identified C4.4A as a substrate to both metalloproteases. C4.4A is a member of the Ly-6 family originally identified in a screening designed to select membrane proteins differentially expressed on metastatic pancreatic adenocarcinoma cells (Rosel et al., 1998) . It is a structural homolog of the urokinase-type plasminogen activator receptor (uPAR), which is involved in extracellular proteolysis during cancer invasion (Romer et al., 2004) . C4.4A has been recently proposed as a candidate marker for colorectal cancer (Paret et al., 2007) and its expression correlates with poor prognosis in non-small cell lung cancer (Hansen et al., 2007) . Since C4.4A is considered a cell adhesion molecule that binds to laminins 1 and 5 and Galectin 3 supporting cell migration (Paret et al., 2005) , its identification as an ADAM10 and -17 substrate indicates the involvement of these metalloproteases in the regulation of cell adhesion and migration.
Results

Generation of cells defective in ADAM10 or ADAM17
To identify novel substrates, we generated breast cancer cell lines in which ADAM10 or ADAM17 could be conditionally knocked down. Hence, we stably transfected MCF7-Tet cells with vectors encoding shRNAs targeting ADAM10 or ADAM17 from a promoter regulated by doxycycline. The levels of both metalloproteases were analyzed in different clones from the resulting transfectants by Western blot with specific antibodies (Figure 1 ). ADAM10 and -17 are synthesized as zymogens containing a prodomain that is cleaved during transport through the secretory pathway by furin-like convertases (Borroto et al., 2003) . As previously shown (see for example BechSerra et al., 2006) , the 70-kDa species corresponds to mature ADAM10 devoid of prodomain. In the case of ADAM17, two species, identified as the proform (130 kDa) containing the prodomain and the mature form (105 kDa) lacking it, were detected with specific antibodies (Figure 1 ).
The levels of ADAM17 were unaffected in cells transfected with ADAM10 shRNAs and, conversely, the levels of ADAM10 were unaffected in cells expressing ADAM17, shRNAs. Thus, despite the high level of homology between these proteases, we conclude that the shRNAs used to target these metalloproteases were specific.
A profound reduction in the levels of ADAM10 and -17 was achieved in both types of cells treated with doxycycline, as compared to control cells transfected with scrambled shRNA (Figure 1) . However, in all clones analyzed, we regularly observed a slight downregulation in the levels of the metalloproteases even in the absence of doxycycline, compared to scrambled shRNA cells (data not shown and Figure 1 , lower panel). This fact is likely due to the high efficiency of the shRNAs used in combination with the leakiness of the promoter. We selected two clones with a clear conditional downregulation of ADAM10 and ADAM17 upon doxycycline addition (Figure 1 ).
SILAC rationale and workflow
To identify novel substrates of ADAM10 and -17, we carried out a proteomic screening based on liquid chromatography-mass spectrometry, in combination with differential isotopic labeling of cells. We chose SILAC because, in contrast to ICAT (Isotope-Coded Affinity Tagging)-based strategies, it allows the usage of amino acids of higher abundance than cysteine. In addition, it does not require chemical derivatization and as a consequence quantification is not biased by labeling efficiency. (A) Schematic representation of the performed SILAC protocol. Two cell populations are grown in PETG expanded surface roller bottles during 7 days, supplied with either 'light' lysine and 'medium' arginine compared to 'heavy' amino acids. Labeled amino acids are incorporated in the cell proteome through metabolic labeling using the cell's own protein apparatus, ruling out technical variations from the labeling procedure encountered, e.g., in DIGE or ICAT techniques. Inhibiting ADAM10 or ADAM17 was carried out in combination with the 'light' condition, untreated cells were labeled 'heavy'. After labeling, supernatants were pooled and incubated with agarose-bound lectin WGA, binding to glycosylated proteins. Glycoproteins were eluted by competition with N-acetyl glucosamine and separated by SDS-PAGE. To reduce complexity for mass spectrometric analysis, the gel is cut in 20 slices, and proteins are trypsinized and loaded in the ion trap mass spectrometer after reverse phase chromatography. (B) Evaluation of the SILAC procedure by plotting peptide ratio frequency distribution. Log H/L ratio values are plotted against number of peptides. A logarithmic scale was used to make the distribution symmetric. Since most proteins and therefore most tryptic peptides should be unaffected by the specific shRNA treatments we apply, it follows that their H/L ratio approaches 1 (Log 1s0). Plotted for all peptide ratios, this translates into a Gaussian distribution peaking at Log 1s0.
For ADAM17, we compared the conditioned media of the shRNA clone in the presence and absence of doxycycline. However, considering the leakiness of the knockdown system we used an alternative approach when looking for substrates of ADAM10. In this case, the shRNA clone was compared with control cells transfected with the scrambled shRNA, both in the presence of doxycycline.
The labeling protocol consisted of growing ADAM10 or -17 knock-down cells in the presence of unlabeled lysine and 15 N 4 'medium' arginine and control cells in the presence of the heavy isotopes of these amino acids ( Figure  2A ). The usage of two different amino acids increases the probability that a given peptide incorporates labeled amino acids. Of note is that both conditions (knock-down and control cells) were labeled isotopically for arginine ( 15 N 4 'medium' arginine and 13 C 6 15 N 4 'heavy' arginine). This allowed us to discard contaminant peptides originating from the serum, which remain unlabeled and therefore contain only 'light' arginine.
Typically, during transport to the plasma membrane, the extracellular domain of the substrates of ADAM10 and -17 is glycosylated. Previous reports have shown the presence of high levels of heat shock proteins, actin and metabolic pathway enzymes in the extracellular medium (Guo et al., 2002) . Since these proteins are not glycosylated, in order to enrich the conditioned media in ADAM10 and -17 substrates, extracellular glycosylated proteins were purified by wheat germ agglutinin (WGA) chromatography ( Figure 2A ). In turn, these proteins were eluted by competition with N-acetylglucosamine and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) ( Figure 2A ). Note that although we used serum-free medium, albumin still remained an important contaminant ( Figure 2A and B insets). However, we found that albumin acted as a carrier, increasing the recovery of peptides (data not shown).
After separation, the gel was cut horizontally in 20 slices and these gel segments were separately processed (see materials and methods section). This procedure reduces the complexity of the peptide mixture analyzed in each liquid chromatography-mass spectrometry (LC-MS) run, increasing the detection probability of low abundant components in the mixture. In addition, it allows an estimation of the molecular weight of the proteins identified.
A total amount of 2001 peptides from 658 individual proteins was identified in the case of ADAM10, while the Upper section: mean H/L ratios in the ADAM10shRNA SILAC screening. Established ADAM10 substrates served as an internal positive control (E-Cadherin, Desmoglein-2 and PTP receptor-type k). All C4.4A peptides (indicated in bold; including the C-terminal QGVEHEASRDEEPR) showed a mean ratio of H/Ls1.96 alerting us to the possibility of a novel ADAM10 substrate. The next proteins in line, Dystroglycan and LISCH protein may very well be ADAM10 substrates, but were not analyzed further. Lower section: mean H/L ratios of proteins in the ADAM17shRNA SILAC screening. Again, Fractalkine and NCAM L1, established ADAM17 substrates, were picked up showing a high H/L ratio and served as an internal control. The H/L ratio of C4.4A peptides (Cterminal peptide excluded) followed directly below with H/Ls1.29, fingering it in addition to being an ADAM10 substrate as a possible new ADAM17 target. The C-terminal QGVEHEASRDEEPR peptide was picked up 3 times and was clearly unaffected by the ADAM17 shRNA, having a ratio H/L of 1.00. Both Annexin A5 and CEACAM5 were not tested because of lower differences from 1, but may also be genuine ADAM17 substrates (nsamount of MS/MS spectra identified from this protein). Mean ratios presented for ADAM17 SILAC are normalized to H/Ls0.89 because of a minor imbalance in H/L distribution (see Figure 2B ). The right column indicates the International Protein Index (IPI) database identification numbers.
ADAM17 experiment yielded 611 peptides from 120 individual proteins. Peptide coverage analysis from individual transmembrane proteins randomly chosen showed only peptides from the extracellular domain (data not shown), ruling out a significant contamination from the cell fraction.
Identification of ADAM10 and -17 substrates
To identify substrates of ADAM10 and -17, we compared the relative abundance of shedding products between the two conditions analyzed. We reasoned that the levels of the majority of secreted glycosylated proteins would be unaffected by the selective shRNAs. We fully confirmed this assumption in the case of ADAM10. Plotted peptide ratios on a distribution histogram showed a Gaussian distribution ( Figure 2B ) peaking at Log H/Ls0, i.e., a ratio H/L of 1. In the case of ADAM17, the plot showed a minor deviation (ratio H/Ls0.89). This deviation may be a technical issue. Alternatively, it may reflect a direct or indirect role of ADAM17 in the regulation of the general secretion and/or turnover of secreted glycosylated proteins.
The results of mass spectrometric analysis showed a number of candidates previously identified as substrates for ADAM10, namely the cell adhesion molecule E-cadherin (Maretzky et al., 2005a) , the desmosomal cadherin Desmoglein-2 (Bech-Serra et al., 2006) and PTP receptor-type k (Anders et al., 2006) (Table 1) . We also detected 29 MS/MS spectra matching peptides from C4.4A (4 different sequences, Figure 3 : black lines), with a mean ratio of 1.96"0.07, making it a candidate for a new ADAM10 substrate.
In the case of ADAM17, we also identified the known substrates Fractalkine (Tsou et al., 2001; Garton et al., 2003) and NCAML1 (Maretzky et al., 2005b) . In addition, we identified several C4.4A peptides (Figure 3 , gray lines). Taken together, the results in Table 1 and Figure 3 indicate that C4.4A may be a novel substrate of both ADAM10 and ADAM17.
The location of the retrieved peptides, and in particular the most C-terminal peptide (QGVEHEASRDEEPR), shows that the cleavage by ADAM10 occurs within the 13 amino acids from the putative GPI incorporation site and that nearly the entire extracellular domain is released. This result is in agreement with the known ability of ADAM10 to cleave proteins in the extracellular juxtamembrane region (Arribas and Borroto, 2002) . Although typically ADAM17 also cleaves transmembrane proteins in the juxtamembrane region, the fact that the H/L ratio of the C-terminal peptide is 1 indicates that the cleavage site by ADAM17 is located N-terminal of this peptide.
Characterization of the shedding of C4.4A
To validate the identification of C4.4A as a substrate of ADAM10 and -17, we used different cell lines and inhibitors. First, we confirmed the results of the proteomic screenings using the cells expressing the shRNAs ( Figure  4A ). Analysis of the conditioned media by Western blot with specific antibodies against C4.4A identified a 90 kDa diffuse band. Although the predicted molecular mass of soluble C4.4A is 36 kDa, it has been previously shown that extensive N-and O-glycosylation leads to a substantial increase in electrophoretic migration (Hansen et al., 2004) , thus we identified the major 90 kDa band as Figure 3 Schematic representation of C4.4A and mapping of peptides identified in SILAC. C4.4A has an N-terminal signal peptide (SP), a C-terminal prodomain (Pro), and two consecutive Ly6/uPAR domains followed by a small protease-sensitive region (Y230-R234, bold residues). C4.4A is attached to the plasma membrane by means of a GPI-anchor at its C-terminus after prodomain removal. Peptides underlined in black were found in ADAM10 SILAC, gray underlined peptides originated from the ADAM17 SILAC screening. soluble C4.4A (sC4.4A, Figure 4) . Comparison of the levels of soluble C4.4A in media conditioned by MCF7 parental cells or the same cells expressing ADAM10 and ADAM17 shRNAs confirmed the results of the proteomic screening ( Figure 4A ) and strongly support the participation of both ADAMs in the shedding of C4.4A.
To confirm the participation of ADAM10 in the cleavage of C4.4A by independent means, we used the prodomain of the metalloprotease. It has been recently shown that the purified prodomain of ADAM10 is a specific inhibitor of the metalloprotease (Moss et al., 2007) . Treatment of cells with this inhibitor induces a dose-response inhibition of sC4.4A production, to levels similar to those achieved through the knock-down of ADAM10, further supporting the role of this metalloprotease in the shedding of C4.4A.
C4.4A is similar to uPAR (43.5% homology at the amino acid level) and uPAR can be cleaved by different proteases, including plasmin, uPA, trypsin, chymotrypsin, elastase, cathepsin G and metalloproteases (Montuori et al., 2005) . To confirm that metalloproteases significantly contribute to the shedding of C4.4A in a different cell line, we made use of two well-characterized metalloprotease inhibitors, the hydroxamate BB94 and 1,10-phenanthroline. Their effect was analyzed on the shedding of C4.4A from A431 cells, derived from a human vulval epithelial carcinoma. Both inhibitors impaired the production of sC4.4A arguing that metalloproteases contribute to the shedding of this molecule also in A431 cells.
The phorbol ester phorbol myristate acetate (PMA) activates ADAM17 by an as yet unknown mechanism (reviewed in Arribas and Borroto, 2002) . Treatment of A431 cells lead to a clear increase in the levels of sC4.4A ( Figure 4D ) that could be prevented by treatment with BB94, showing that a metalloprotease activated by PMA, likely ADAM17, is involved in the shedding of C4.4A also in A431 cells. It has been shown that C4.4A is upregulated upon PMA-induced hyperplasia of mouse skin (Hansen et al., 2004) ; however, treatment of A431 cells with the phorbol ester did not result in an increase in the levels of cell-associated C4.4A ( Figure 4D ). Thus, we concluded that the effect of PMA is not due to an increase in the levels of C4.4A but to an upregulation of the activity of the metalloproteases that cleave C4.4A. Collectively, these results are fully in line with our SILAC data and confirm ADAM10 and ADAM17 as novel C4.4A sheddases.
Discussion
Despite recent advances, the role of metalloproteases during tumor progression and metastasis is far from clear. This lack of understanding can be partially explained by the incomplete knowledge of individual degradomes. Therefore, our group is searching for novel substrates of ADAM10 and -17, two metalloproteases with apparent protumorigenic activities, using different proteomic techniques. Applying DIGE (Difference Gel Electrophoresis), we previously showed that two cell adhesion molecules, Desmoglein-2 and ALCAM are cleaved by these ADAMs . However, despite its advantages, DIGE has limitations inherent to two-dimensional electrophoresis, such as predominant identification of abundant proteins and loss of very big, very small or hydrophobic proteins. To overcome these limitations and identify novel substrates, we carried out a proteomic screening based on LC-MS, in combination with stable isotope labeling of cells expressing specific shRNAs. Using this approach, in addition of known substrates of ADAM10 and -17, we identified the (A) Effect of shRNA downregulation of ADAM10/17 on C4.4A shedding in MCF7 cells. Cells were treated for shRNA activation to downregulate the respective metalloprotease and subsequently the supernatant was analyzed for C4.4A. Cells were lysed in ice-cold 1% Triton X-100 and analyzed for ADAM10 and -17 (a representative experiment out of 4 is shown). Top left panels show ADAM10/ 17 downregulation in the cell fraction illustrating the claimed shRNA specificity, notwithstanding the high homology of their target RNAs. The supernatant from these cells showed lowered C4.4A shedding upon ADAM10 and ADAM17 knock-downs (towards 75% and 50% of normal levels, respectively). This illustrates that both ADAMs are likely C4.4A sheddases. (B) Effect of the ADAM10 prodomain on the shedding of C4.4A. MCF7 cells were treated with different concentrations of the prodomain of ADAM10 and subsequently the supernatant was analyzed for C4.4A by Western blot. The quantifications represent the average of two determinations. (C) Treatment of A431 cells overexpressing ADAM17 with metalloprotease inhibitors (a representative experiment out of 5 is shown). Serum-free supernatants were collected after 2 h incubation, glycoproteins were isolated with WGA and loaded on 8% SDS-PAGE. BB94 (5 mM), a specific metalloprotease inhibitor, blocks C4.4A release to 75% of the steady state, verifying C4.4A as a metalloprotease substrate. Moreover, adding 500 mM phenantroline, a broad-range metalloprotease inhibitor, reduces shedding more than 2-fold, again showing the involvement of metalloproteases. Since shedding is not blocked fully by these inhibitors, it is assumed that also other, non-metalloprotease enzymes are responsible for C4.4A release, e.g., phospholipases. (D) C4.4A shedding can be stimulated in A431 cells by PMA, a known activator of metalloproteases. Stimulating metalloproteases upregulate C4.4A shedding and BB94 abolishes this effect. Analysis of the cellular fraction did not show detectable differences in C4.4A presence upon PMA stimulation. Quantifications were normalized against C4.4A in the untreated supernatant. metastasis-associated protein C4.4A as a novel substrate.
In principle, the search for novel substrates could be carried out by analyzing cell membranes or conditioned media. The ectodomain of the vast majority of proteins cleaved by ADAM10 and -17 is released to the extracellular medium, while the transmembrane/cytoplasmic stub is left behind. Pilot experiments showed that identifying the stub is difficult, mainly because of technical limitations in plasma membrane isolation that result in low specific protein yields. Furthermore, because of its dynamic nature, the plasma membrane is continuously replenishing shed proteins with intact ones, interfering with the final readout (data not shown). Therefore, we opted to analyze the supernatant, which is easily isolated and represents a more stable pool of proteins.
Although the use of shRNAs is most appropriate to knock down a specific metalloprotease, the use of doxycycline to regulate an inducible promoter can interfere with metalloprotease activity. Doxycycline is an inhibitor of MMPs, particularly MMP-2 and -9 (Golub et al., 1991; Gilbertson-Beadling et al., 1995) at concentrations of 5-10 mg/ml. Therefore, to avoid a possible inhibitory effect, we used 10 ng/ml doxycycline, the lowest dose that still represses the targeted metalloproteases. This concentration of doxycycline has no effect on the shedding of C4.4A or Desmoglein-2, another substrate of ADAM10 and -17 (data not shown).
Despite intense effort, our understanding of the regulation of protein ectodomain shedding is still rudimentary. Several physiological and non-physiological activators can increase the shedding of many cell surface proteins; however, the underlying factors and mechanisms are unknown (Arribas and Borroto, 2002) . Our results on the shedding of C4.4A, a GPI-anchored protein, showing activation by PMA, clearly demonstrate that activation does not require substrates with transmembrane or cytoplasmic domains and that activation very likely occurs via the metalloprotease and not by increasing the availability of the ligand. This is in agreement with the concept that the substrates of ADAM10 and -17 are selected on the basis of the extracellular juxtamembrane region (Arribas et al., 1997) and with the accumulating evidence that several GPI-anchored proteins are legitimate ADAM substrates (Hattori et al., 2000; Vincent et al., 2001) .
The H/L ratio of the carboxy terminal peptide in ADAM17 knock-down cells and control cells is 1, showing that cleavage site of this metalloprotease is likely Nterminal of this peptide. It has been previously shown that a trypsin/chymotrypsin-sensitive stretch (Y230 to R234) is located between two clusters of N-and O-linked carbohydrates (Hansen et al., 2004) implying the exposure of this domain to proteases. The cleavage site of ADAM17 could be located in this protease sensitive region.
The homology of C4.4A to the uPA receptor and their close genetic linkage on 19q13.2 (Borglum et al., 1992; Wurfel et al., 2001 ) suggests a common origin. It is appealing to hypothesize that C4.4A may exert functional activity similar to uPAR, which is known to play an important role in a variety of physiological and pathological processes requiring cell migration and tissue remodeling (Andreasen et al., 1997; Blasi, 1997; Plesner et al., 1997; Reuning et al., 1998; Wang et al., 1998) . Furthermore, uPA-uPAR can activate matrix degrading enzymes and it has been described that C4.4A can also interact weakly with the uPA (Rosel et al., 1998) , providing a possible tumorigenic mechanism. However, this remains controversial and has been contradicted by Hansen and coworkers using plasmon resonance (Hansen et al., 2004) . At any rate, the identification of C4.4A as a substrate of ADAMs unveils a novel level of regulation. By promoting its release from the plasma membrane, ADAMs regulate the physical location of C4.4A, facilitating its extracellular diffusion. Interestingly E-cadherin, another ADAM10 substrate was recently shown to colocalize with C4.4A in normal esophageal mucosa (Hansen et al., 2008) . Both proteins are downregulated upon malignant transformation, hinting at a common regulation. The results shown here open the possibility that ADAMs contribute to this downregulation.
In addition to its possible function, several lines of evidence indicate that C4.4A plays a role in tumor invasion and metastasis. Hansen and colleagues proved it to be a poor prognosis marker for non-small cell lung cancer (NSCLC) (Hansen et al., 2007) , this is especially noteworthy given the late stages in which NSCLC is detected in and the subsequent poor survival rates of C4.4A positive patients. Similarly, in melanoma progression, Seiter et al. demonstrated a correlation with C4.4A expression, where up to 60% of primary malignant melanoma and 100% of lymph node and skin metastases were shown to be C4.4A positive . Recently, colorectal cancer was added to the growing list of C4.4A expressing tumor types (Paret et al., 2007) . These data and the fact that we now uncover C4.4A as a substrate of ADAM10 and -17 is beginning to shed light on the consequences of ADAM overexpression frequently observed in metastatic tumor tissue and calls for a continued effort in mapping the ADAM degradomes.
Materials and methods
Antibodies and reagents
The polyclonal antibodies against the intracellular domain of ADAM17 have been described elsewhere , in addition we used anti-ADAM17 from Chemicon (Temecula, USA). Rabbit anti-ADAM10 C-terminus was a gift from S. Riedle and P. Altevogt (Deutsches Krebsforschungszentrum, Heidelberg, Germany). Polyclonal anti-C4.4A was a gift from M. Plough (Finsen Laboratory, Copenhagen, Denmark). Additional chemicals were from Sigma-Aldrich (St. Louis, MO, USA). SILAC culture medium and amino acids were from Invitrogen (Carlsbad, USA).
shRNA design
In total, 59-nucleotide shRNA oligonucleotides were used to express ADAM10 and ADAM17 specific RNA hairpins. Upon annealing, the oligos form a cassette flanked by BglII and XhoI sticky ends, allowing for the directional insertion in pSUPERIOR (OligoEngine, Seattle, USA). shRNA transcription starts theoretically at nucleotide 7, the transcribed hairpin is formed by 19 nucleotides coding for the target protein followed by a 9-nucleotide spacer and the reverse complement of the target sequence. Two different hairpins were designed for each target, and as a control a scrambled shRNA was included bearing no homology to any known mammalian mRNA in the NCBI database.
( 
Cell lines and transfections
Cells were grown in Dulbecco's modified Eagle's medium (DMEM)-F12 (1:1) (GIBCO, Carlsbad, USA) supplemented with 10% fetal calf serum (FCS) and 2 mM L-glutamine. This mixture leaving out serum was used in serum free conditions. Transient and stable transfections were performed using Fugene-6 transfection reagent (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions. For ADAM10 and ADAM17 downregulation, MCF7 Tet cells (Clontech, Mountain View, USA) were transformed with the pSUPERIOR vector (OligoEngine), containing ADAM10 shRNA, ADAM17 shRNA or a scrambled hairpin as a control (Figure 2A ). Cell lines responding to doxycycline and maximally downregulating ADAM10 or -17 were selected by Western blotting (Figure 1 ) and grown in larger quantities for use in the SILAC screening. A431 cells (human squamous carcinoma) (Giard et al., 1973) were purchased from the American Type Culture Collection (ATCC CRL 1555).
Analysis of shedding of C4.4A in MCF7 shRNA cells
For Western blot analysis, cells were plated in 60-mm dishes in DMEM-F12q10% FCS. After 24 h, cells were incubated with serum-free DMEM (identical to SILAC conditions) and treated in the presence or absence of doxycycline for 48 h. After that, for ADAM10 and ADAM17 detection, the cells were lysed for 30 min in ice-cold 1% Triton X-100 (TX-100) and kept on ice in further steps to avoid unwanted proteolytic activity. As a control, the TX-100 insoluble pellet was resuspended in SDS-PAGE sample buffer and directly loaded on gel. Total protein in the lysates was quantified, and equal amounts of protein from cell lysates were concentrated with WGA-agarose beads (Vector Laboratories, Burlingame, CA, USA) or Concanavaline-A beads (GE Healthcare, Giles, UK) rotating for 2 h at 48C. Proteins were eluted directly in SDS-PAGE sample buffer. For the TX-100 insoluble fraction, only a very low signal compared to TX-100 soluble C4.4A was observed, confirming that the majority of C4.4A is solubilized (data not shown). In parallel, for the detection of shedded C4.4A, the conditioned medium of the cells was collected and concentrated on WGA-agarose as described above. Protein loading of conditioned medium samples for Western blot analysis was adjusted according to the total protein in cell lysates and checked by Ponceau red staining of the blotted membrane.
Treatment with protease inhibitors and PMA
Cells were treated with 5 mM BB94 (a specific metalloprotease inhibitor; British Biotech, Oxford, UK), 500 mM phenantroline and/or 1 mM PMA for the indicated times, and the shedding of C4.4A was analyzed as described above. The prodomain-based specific ADAM10 inhibitor has been characterized recently (Moss et al., 2007) .
Western blotting
WGA-agarose-concentrated protein samples from both cell lysate and conditioned medium were loaded onto a 10% SDSpolyacrylamide gel, transferred to nitrocellulose membranes (Bio-Rad, Hercules, USA), and blotted with anti-C4.4A. Concanavalin-A-agarose concentrated protein samples from 1% Triton X-100 cell lysates were loaded onto an 8% SDS-polyacrylamide gel, transferred to nitrocellulose membranes, and blotted with anti-ADAM10 or anti-ADAM17 antibody. Detection was performed using the corresponding horseradish peroxidase-conjugated secondary antibody and the SuperSignal chemiluminescence kit from Pierce (Rockford, IL, USA). Quantifications were performed with the ImageQuant software (GE Healthcare), identical rectangles were used to measure the chemiluminescent signals and one rectangle outside the lanes was used for background setting and finally subtracted from the obtained signals.
SILAC labeling and sample preparation
Cells were seeded in SILAC DMEM medium supplemented with dialyzed serum (amino acid free) and the appropriate normal or isotopically labeled amino acids. To increase protein yield, we opted for growing cells in expanded-surface polyethylene terephthalate glycol roller bottles (NUNC, Roskilde, Denmark) using a Bellco vault-type rotating incubator. In both the ADAM10 and -17 SILAC, we chose 'light' lysine and 15 N 4 arginine 'medium' amino acids for the knock-down condition (for simplicity referred to as the 'light' condition) and 13 C 6 Lysq 13 C 6 15 N 4 Arg 'heavy' amino acids for the untreated condition (referred to as the 'heavy' condition). The culture conditions were first optimized for maximal isotopic incorporation and to minimize arginine to proline conversion. In general, cells were incubated for a total of 7 days, corresponding to 6 cell doublings, the final 48 h without dialyzed serum to reduce serum protein background. In addition, cells were seeded so that they reached confluency on day 7 to maximize protein yields. ADAM10/ 17shRNA cells were grown in the presence or absence of doxycycline the last 4 days (2 days still in the presence of dialyzed serum, and the final 2 days serum free) to initialize shRNA translation. Cells were washed twice with phosphate buffered saline (PBS) and harvested in PBSq10 mM EDTA. Cells were counted and the amount of cells and supernatants were equalized according to this. Large differences ()5%) in cell counts between treated and untreated conditions, possibly due to toxic effects of the shRNA did not occur and would have compromised the screening by introducing extra background or imbalance. After this, the supernatant of control and shRNA treated cells are pooled and further technical bias will therefore have equal effects on both protein pools, leaving the H/L ratio unaffected. Conditioned media were incubated overnight at 48C with WGA-agarose beads (1 ml of stirred suspension per ml of conditioned medium). Glycoproteins were eluted by rotating for 2 h at 48C with 4 ml of 0.5 M N-acetylglucosamine in 10 mM HEPES (pH 7.5), 0.15 M NaCl buffer. The glycoprotein solutions were then concentrated 40-fold by ultrafiltration (Amicon Ultra-4, 5 kDa cut-off; Millipore, Carrigtwohill, Ireland). Urea was then added to the concentrated protein solution to a final 8 M concentration and pH was adjusted to 8.5. Proteins were reduced by addition of 50 mM dithiothreitol and incubation for 30 min at room temperature, and then carbamidomethylated with 125 mM iodoacetamide for 1 h at room temperature. The protein mixture was then purified by a modified acetone-trichloroacetic acid precipitation (2D-CleanUp kit; GE Healthcare). The protein pellet was resuspended in 40 ml of SDS-PAGE loading buffer and subjected to 1D electrophoresis on a 10% polyacrylamide-SDS gel.
Liquid chromatography-mass spectrometric analysis
The 1D-gel lanes were cut into 20 horizontal slices and each slice was subjected to in-gel tryptic digestion using modified porcine trypsin (Promega, Madison, USA). The digests were then analyzed on an Esquire HCT IT mass spectrometer (Bruker, Bremen, Germany), coupled to a nano-HPLC system (Ultimate, LC Packings, Amsterdam, The Netherlands). Peptide mixtures were first concentrated on a 300 mm i.d., 1 mm PepMap nanotrapping column and then loaded onto a 75 mm i.d., 15 cm PepMap nanoseparation column (LC Packings). Peptides were then eluted by an acetonitrile (ACN) gradient (0-60% B in 150 min, where B is 80% ACN, 0.1% formic acid in water; flow rate ca. 300 nl/min) through a PicoTip emitter nanospray needle (NewObjective, Woburn, MA, USA) onto the nanospray ionization source of the IT mass spectrometer. MS/MS fragmentation (1.9 s, 100-2800 m/z) was performed on two of the most intense ions, as determined from a 1.2 s MS survey scan (310-1500 m/z), using a dynamic exclusion time of 1.2 min for precursor selection and excluding single-charged ions. An automated optimization of MS/MS fragmentation amplitude, starting from 0.60 V was used.
Protein identification and data analysis
Data processing for protein identification and quantitation was performed using WARP-LC 1.1 (Bruker), a software platform integrating LC-MS run data processing, protein identification through database search of MS/MS spectra and protein quantitation based on the integration of the chromatographic peaks of MS extracted ion chromatograms for each precursor. Proteins were identified using Mascot (Matrix Science, London, UK) to search the International Protein Index (IPI)-Human 3.26 database (67 665 sequences, 28 462 007 residues) (Kersey et al., 2004) . MS/MS spectra were searched with a precursor mass tolerance of 1.5 Da, fragment tolerance of 0.5 Da, trypsin specificity with a maximum of 1 missed cleavage, carbamidomethylation set as fixed modification and methionine oxidation and the corresponding Lys and Arg SILAC labels as variable modifications. A positive identification criterion was set as an individual Mascot score for each peptide MS/MS spectrum higher than the corresponding homology threshold score. For protein quantitation (H/L) ratios were calculated averaging the measured (H/L) ratios for the observed peptides, after discarding outliers. For selected proteins of interest, quantitation data obtained from the automated WARP-LC analysis were manually reviewed.
